# Intranasal Bevacizumab for HHT-Related Epistaxis

> **NCT02389959** · PHASE4 · COMPLETED · sponsor: **Stanford University** · enrollment: 40 (actual)

## Conditions studied

- HHT
- Hereditary Hemorrhagic Telangiectasia
- Epistaxis
- Nose Bleeds
- Nasal Bleeding

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Placebo (Saline)

## Key facts

- **NCT ID:** NCT02389959
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-04
- **Primary completion:** 2020-01-23
- **Final completion:** 2020-01-23
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02389959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02389959, "Intranasal Bevacizumab for HHT-Related Epistaxis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02389959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*